MediWound

Enzymatic Therapeutics for Non-Surgical Tissue Repair

Health Tech & Life Sciences
Public on NASDAQ on Mar, 2014

Company Overview

Snapshot

Founded in January 2000, MediWound operates with 51–200 employees and has raised a total of $198.72 million across 8 funding rounds. The company went public on NASDAQ in March 2014.

Business overview

MediWound is a global biotechnology company focused on pioneering enzymatic, non-surgical therapies for tissue repair. Its core product, NexoBrid, is an FDA-approved biologic for the enzymatic removal of eschar in thermal burns, marketed across the United States, European Union, Japan, and other international markets. The company is also developing EscharEx, an investigational therapy for chronic wound debridement, aiming to establish a new standard of care in wound management. MediWound operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology, targeting healthcare providers and patients.

Strategic signal

In November 2025, MediWound successfully completed the commissioning of its expanded GMP manufacturing facility for NexoBrid. This operational milestone indicates the company's commitment to scaling production and meeting growing demand for its FDA-approved biologic, signaling strong commercial momentum and readiness for broader market penetration to investors.

Company Intelligence Q&A

What is MediWound's primary therapeutic focus?
MediWound specializes in enzymatic, non-surgical therapies for tissue repair, with its lead product NexoBrid indicated for the enzymatic removal of eschar in thermal burns.
When did MediWound go public?
MediWound went public on NASDAQ in March 2014.
What significant funding event occurred in July 2024?
In July 2024, MediWound received funding from Mölnlycke Health Care, which invested $15 million, and Yalin Lapidot.
What is the status of MediWound's pipeline product, EscharEx?
EscharEx is an investigational therapy for the debridement of chronic wounds and is currently in a Phase III study, as announced in October 2023 in collaboration with 3M.
What was a key operational development for NexoBrid in November 2025?
In November 2025, MediWound successfully completed the commissioning of its expanded GMP manufacturing facility for NexoBrid, enhancing its production capabilities.

External links